18F-FDOPA PET for the diagnosis of parkinsonian syndromes
- PMID: 25366711
18F-FDOPA PET for the diagnosis of parkinsonian syndromes
Abstract
18F-FDOPA PET has been historically used for the evaluation of parkinsonian syndromes in research settings. With the wider availability of PET cameras and 18F-DOPA this method can be used as a clinical diagnostic tool. Current acquisition protocols are simple with a 10 minute static acquisition performed 90 minutes post injection. Criteria for precise visual analysis of the images are defined. The performances of the method are reviewed throughout the literature. The method is very sensitive for detection of IPD versus normal patients. Few studies comparing 18F-FDOPA PET and DAT SPECT did not show any difference in diagnostic accuracy. 18F-FDOPA PET is reliable for evaluation of IPD progression. In general, atypical Parkinson's syndromes cannot be reliably differentiated from IPD since they share a similar nigro-striatal degeneration process. However, some patterns such as the asymmetrical faint homogeneous striatal uptake reduction pattern of CBD can be recognized. The short acquisition protocol, the various indications in oncology of 18F-FDOPA and the high quality of PET images are in favor of this technique in daily clinical practice for the improvement of diagnosis of parkinsonian syndromes.
Similar articles
-
18F-FDOPA PET imaging of brain tumors: comparison study with 18F-FDG PET and evaluation of diagnostic accuracy.J Nucl Med. 2006 Jun;47(6):904-11. J Nucl Med. 2006. PMID: 16741298 Clinical Trial.
-
Intrastriatal gradient analyses of 18F-FDOPA PET scans for differentiation of Parkinsonian disorders.Neuroimage Clin. 2020;25:102161. doi: 10.1016/j.nicl.2019.102161. Epub 2020 Jan 3. Neuroimage Clin. 2020. PMID: 31981888 Free PMC article.
-
99mTc-TRODAT-1 SPECT in healthy and 6-OHDA lesioned parkinsonian monkeys: comparison with 18F-FDOPA PET.Nucl Med Commun. 2003 Jan;24(1):77-83. doi: 10.1097/00006231-200301000-00018. Nucl Med Commun. 2003. PMID: 12501023
-
3,4-dihydroxy-6-[18f]-fluoro-L-phenylalanine positron emission tomography in patients with central motor disorders and in evaluation of brain and other tumors.Semin Nucl Med. 2007 Nov;37(6):440-50. doi: 10.1053/j.semnuclmed.2007.08.002. Semin Nucl Med. 2007. PMID: 17920351 Review.
-
Nuclear Imaging in the Diagnosis of Clinically Uncertain Parkinsonian Syndromes.Dtsch Arztebl Int. 2019 Nov 1;116(44):747-754. doi: 10.3238/arztebl.2019.0747. Dtsch Arztebl Int. 2019. PMID: 31774054 Free PMC article. Review.
Cited by
-
[18F]FDOPA PET/CT in Solid Pseudopapillary Tumor of the Pancreas: a Recurred Tumor Mimicking Splenosis.Nucl Med Mol Imaging. 2024 Apr;58(2):81-85. doi: 10.1007/s13139-023-00826-1. Epub 2023 Oct 5. Nucl Med Mol Imaging. 2024. PMID: 38510822
-
Dopamine Synthesis in the Nigrostriatal Dopaminergic System in Patients at Risk of Developing Parkinson's Disease at the Prodromal Stage.J Clin Med. 2024 Feb 2;13(3):875. doi: 10.3390/jcm13030875. J Clin Med. 2024. PMID: 38337569 Free PMC article.
-
Covering Basic Needs on Molecular Imaging.Mov Disord Clin Pract. 2024 Jan;11(1):10-13. doi: 10.1002/mdc3.13905. Epub 2023 Nov 29. Mov Disord Clin Pract. 2024. PMID: 38291843 No abstract available.
-
[18F]-FDopa positron emission tomography imaging in corticobasal syndrome.Brain Imaging Behav. 2023 Dec;17(6):619-627. doi: 10.1007/s11682-023-00789-z. Epub 2023 Jul 21. Brain Imaging Behav. 2023. PMID: 37474673
-
Automatic Production of [18F]F-DOPA Using the Raytest SynChrom R&D Module.Pharmaceuticals (Basel). 2022 Dec 22;16(1):10. doi: 10.3390/ph16010010. Pharmaceuticals (Basel). 2022. PMID: 36678506 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources